Results 41 to 50 of about 1,168 (170)
The EES‐Q provides meaningful information on multidimensional HRQoL in one single instrument to improve patient‐centred health care. Social HRQoL warrants extra attention as patients with pituitary adenoma experience the most inconveniences in social HRQoL preoperatively and during follow‐up. Abstract Objective Social functioning is an important factor
Gonneke E. Joustra +5 more
wiley +1 more source
Prolactin-secreting adenomas (prolactinomas) are the most common secreting adenomas of the pituitary. Microprolactinomas (diameter <10 mm) are frequently diagnosed in women, whereas macroprolactinomas (maximum diameter ≥10 mm) are generally seen in men. Most macroprolactinomas measure between 10 and 40 mm.
openaire +2 more sources
Giant pubertal prolactinoma: Complete resolution following short term carbegoline treatment [PDF]
Prolactinomas are the most common pituitary tumors but rarely seen in adolescent males. There is no indication for surgery both in micro‑ and macro‑adenomas unless an urgent treatment is necessary.
Tuzun, D, Gul, K, Oguz, A, Sahin, M
core +2 more sources
Atypical Giant Suprasellar Prolactinoma Presenting With Visual Field Changes in the Absence of Symptoms of Hyperprolactinemia [PDF]
Prolactinomas are benign tumors that make up the majority of all pituitary adenoma cases and present most commonly in women. Prolactinomas presenting in adolescents and children, however, are extremely rare.
Mo, Jun Q +3 more
core +1 more source
Update in Pathogenesis, Diagnosis, and Therapy of Prolactinoma [PDF]
SIMPLE SUMMARY: This review updates recent advances in the pathogenesis, diagnosis, and therapy of prolactinoma. Prolactinomas, comprising 30–50% of all pituitary neuroendocrine tumors, frequently occur in females aged 20 to 50 and cause hypogonadism and
Nishiyama, Mitsuru +5 more
core +1 more source
Giant prolactinoma case with side effects due to cabergoline [PDF]
Dopamine agonists should usually be the first treatment for patients with prolactinomas of all sizes, because these drugs decrease serum prolactin concentrations and decrease the size of most lactotroph adenomas. Cabergoline is preferred first.
Hüseyin Dursun +3 more
core +1 more source
Comparison of the effects of medical and surgical treatments in giant prolactinoma: A single-center experience [PDF]
Purpose Giant prolactinomas, which have extremely large sizes and high prolactin (PRL) values, are rarely seen. Although medical therapy is effective, surgical treatment is more frequently applied due to slightly lower response rates and compression ...
Hakyemez, Bahattin
core +1 more source
Giant prolactinoma, a case report and review of the literature
A 13 year old boy presented with acute onset of sudden severe headache and visual impairment following a one-year history of intermittent frontal headache. Serum prolactin level was 17532ng/ml (normal 3–24ng/ml). Magnetic resonance imaging showed a large
Doua K. Al Homyani +4 more
doaj +1 more source
miR‐34a is upregulated in AIP‐mutated somatotropinomas and promotes octreotide resistance
Abstract Pituitary adenomas (PAs) are intracranial tumors associated with significant morbidity due to hormonal dysregulation, mass effects and have a heavy treatment burden. Growth hormone (GH)‐secreting PAs (somatotropinomas) cause acromegaly‐gigantism.
Eva‐Maria Bogner +8 more
wiley +1 more source
A Case of Giant Prolactinoma Presented as a Nasopharyngeal Mass
Giant prolactinomas may present with atypical tumor mass effects, as they are characterized by massive extrasellar invasion. Nasopharyngeal involvement of prolactinoma is a rare condition and it has been described in some case reports in the literature ...
Alev Selek +4 more
doaj +1 more source

